Analysts predict that CRISPR Therapeutics AG (NASDAQ:CRSP) will report sales of $4.69 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for CRISPR Therapeutics' earnings, with the lowest sales estimate coming in at $150,000.00 and the highest estimate coming in at $17.80 million. CRISPR Therapeutics posted sales of $77.02 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 93.9%. The company is expected to issue its next quarterly earnings report on Wednesday, February 10th.

According to Zacks, analysts expect that CRISPR Therapeutics will report full-year sales of $4.81 million for the current year, with estimates ranging from $350,000.00 to $18.10 million. For the next financial year, analysts forecast that the company will report sales of $32.63 million, with estimates ranging from $600,000.00 to $90.00 million. Zacks' sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for CRISPR Therapeutics.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($0.14). CRISPR Therapeutics had a negative net margin of 273.10% and a negative return on equity of 20.72%. The company had revenue of $0.15 million during the quarter, compared to analyst estimates of $2.22 million. During the same period in the prior year, the company earned $2.40 earnings per share. The company's revenue was down 99.9% on a year-over-year basis.

A number of equities analysts have weighed in on the company. Canaccord Genuity upped their target price on CRISPR Therapeutics from $110.00 to $120.00 in a research note on Thursday, October 22nd. Stifel Nicolaus upped their target price on CRISPR Therapeutics from $75.00 to $93.00 and gave the stock a "hold" rating in a research note on Wednesday, October 21st. Bank of America started coverage on CRISPR Therapeutics in a research note on Monday, October 5th. They issued a "buy" rating and a $110.00 target price on the stock. Raymond James reiterated a "sell" rating on shares of CRISPR Therapeutics in a report on Friday, October 30th. Finally, Roth Capital upped their price objective on CRISPR Therapeutics from $105.00 to $115.00 and gave the stock a "buy" rating in a report on Wednesday, October 21st. Two research analysts have rated the stock with a sell rating, three have given a hold rating and fourteen have given a buy rating to the company's stock. The stock has a consensus rating of "Buy" and an average price target of $101.20.

Shares of NASDAQ CRSP opened at $147.54 on Friday. The firm has a market capitalization of $10.42 billion, a P/E ratio of -45.26 and a beta of 2.36. The stock's 50-day simple moving average is $104.98 and its two-hundred day simple moving average is $87.56. CRISPR Therapeutics has a twelve month low of $32.30 and a twelve month high of $151.11.

In other CRISPR Therapeutics news, Director Bradley J. Phd Bolzon sold 8,965 shares of the business's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $86.98, for a total transaction of $779,775.70. Following the sale, the director now directly owns 7,391 shares of the company's stock, valued at $642,869.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Rodger Novak sold 100,000 shares of the business's stock in a transaction that occurred on Monday, November 30th. The stock was sold at an average price of $125.00, for a total value of $12,500,000.00. Following the sale, the president now directly owns 698,007 shares in the company, valued at $87,250,875. The disclosure for this sale can be found here. Over the last three months, insiders have sold 136,000 shares of company stock worth $15,591,523. Insiders own 21.40% of the company's stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Vigilant Capital Management LLC bought a new stake in CRISPR Therapeutics during the third quarter worth approximately $25,000. Webster Bank N. A. purchased a new stake in shares of CRISPR Therapeutics in the third quarter valued at approximately $27,000. Pacitti Group Inc. purchased a new stake in shares of CRISPR Therapeutics in the second quarter valued at approximately $32,000. WASHINGTON TRUST Co boosted its holdings in shares of CRISPR Therapeutics by 81.9% in the second quarter. WASHINGTON TRUST Co now owns 473 shares of the company's stock valued at $35,000 after purchasing an additional 213 shares during the period. Finally, Nachman Norwood & Parrott Inc purchased a new stake in shares of CRISPR Therapeutics in the third quarter valued at approximately $42,000. 55.19% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.

Further Reading: What is the market perform rating?

Get a free copy of the Zacks research report on CRISPR Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CRISPR Therapeutics (NASDAQ:CRSP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

10 Rock-Solid Dividend Paying Stocks to Own

Historically low-interest rates have made it difficult over the last decade for income-oriented investors that want to generate safe cash flow for their retirements.

Dividend-paying stocks have become more appealing to income investors because of their competitive yields, the favorite tax treatment that dividends receive, and their ability to grow their payouts over time. While fixed interest rates from bond investments will lose purchasing power to inflation over time, the purchasing power of income from dividend growth stocks is more protected because companies tend to raise their dividend payments every year.

In this slideshow, we look at ten of the best high-dividend stocks that offer strong yields (above 3.5%), have consistent cash flow, and a strong track record of dividend growth. The companies in this slideshow have all raised their dividend every year for the last ten years.

These companies also have low payout ratios (below 75%), meaning that they will have the ability to continue to pay their dividend if their earnings have a temporary dip.

Stock prices will always fluctuate, but the dividends paid by these rock-solid dividend payers should remain secure with moderate earnings growth.

View the "10 Rock-Solid Dividend Paying Stocks to Own".



Source link